Trial
NCT06902246
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Miami
Collaborators
Bayer
Condition
Unresectable Hepatocellular Carcinoma
Intervention
Regorafenib
Why stopped
Investigator decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-15